Potentsial'nye vozmozhnosti metformina v profilaktike i lechenii onkologicheskikh zabolevaniy u bol'nykh sakharnym diabetom 2 tipa
Diabetes mellitus is associated with increased risk of several types of cancer, and also with increased cancer mortality. Chronic hyperinsulinemia plays the main pathogenetic role in this association, which is mediated by a number of molecular mechanisms, described in this issue. Drugs that increase...
| Format: | Article |
|---|---|
| Language: | English |
| Published: |
Endocrinology Research Centre
2011-03-01
|
| Series: | Ожирение и метаболизм |
| Subjects: | |
| Online Access: | https://endojournals.ru/index.php/omet/article/view/5190 |
| Summary: | Diabetes mellitus is associated with increased risk of several types of cancer, and also with increased cancer mortality. Chronic
hyperinsulinemia plays the main pathogenetic role in this association, which is mediated by a number of molecular mechanisms, described
in this issue. Drugs that increase insulin sensitivity and reduce hyperinsulinemia (metformin in the first place) display anticancer
effect. Aside from the anticancer effect, mediated by reduction of insulin resistance, metformin may directly suppress cancer cells
growth and proliferation via stimulation of AMP kinase (AMPK). Antiproliferative action of metformin in breast and ovarian cancer is
confirmed in a number of experimental and clinical trials. Its found out that therapeutic effect of metformin in treatment of breast cancer
depends on the presence/absence of some molecular features of the tumor (for example, increased expression of HER2 and/or activation
of p70S6K1). In order to specify mechanisms of action and effects of metformin in oncological practice several trials are being conducted
or planned, most of all, in all subtypes of breast cancer. Confirmation of the anticancer effectiveness of metformin will promote an expansion
of its use in clinical practice and in clinical oncology, particularly. |
|---|---|
| ISSN: | 2071-8713 2306-5524 |